HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Angiotensin receptor neprilysin inhibitor treatment is safe and potentially efficacious in end‑stage hypertrophic cardiomyopathy.

AuthorsPaweł Rubiś, Sylwia Wiśniowska-Śmiałek, Katarzyna Holcman, Agata Leśniak-Sobelga, Magdalena Kostkiewicz, Piotr Podolec
JournalPolish archives of internal medicine (Pol Arch Intern Med) Vol. 127 Issue 3 Pg. 216-218 (03 21 2017) ISSN: 1897-9483 [Electronic] Poland
PMID28322217 (Publication Type: Letter)
Chemical References
  • Aminobutyrates
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Enalapril
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination
Topics
  • Aminobutyrates (pharmacology)
  • Angiotensin Receptor Antagonists (pharmacology)
  • Angiotensin-Converting Enzyme Inhibitors (pharmacology)
  • Biphenyl Compounds
  • Cardiomyopathy, Hypertrophic (drug therapy)
  • Drug Combinations
  • Enalapril (pharmacology)
  • Humans
  • Neprilysin (antagonists & inhibitors)
  • Patient Safety
  • Tetrazoles (pharmacology)
  • Treatment Outcome
  • Valsartan (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: